Form 10-Q Aquestive Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Aquestive Therapeutics (AQST) PT Raised to $24 at RBC Capital
November 7, 2018 7:09 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $24.00 (from $23.00) while maintaining an Outperform rating following results.
Stanicky said pending Sympazan launch set to pave the way for lead product Libervant next year.
... More